Skip to main content

Table 1 Baseline characteristics

From: A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma

Characteristics

All patients (n = 46)

Sex

 Male

32 (69.6%)

 Female

14 (30.4%)

Age, years-median (range)

65.5 (43-75)

 > 60

33 (71.7%)

 ≤ 60

13 (28.3%)

Clinical stage

 IIIb

2 (4.3%)

 IVa

3 (6.5%)

 IVb

41 (89.1%)

Previous surgical treatment

 Yes

21 (45.7%)

 No

25 (54.3%)

Metastatic sites

 Distant lymph node

34 (73.9%)

 Lung

16 (34.8%)

 Liver

13 (28.3%)

 Other

11 (23.9%)

Number of metastatic sites

 ≤ 2

31 (67.4%)

 > 2

15 (32.6%)

ECOG PS

 0

15 (32.6%)

 1

31 (67.4%)

  1. Data are presented as the median (IQR) or n (%). ECOG PS Eastern Cooperative Oncology Group Performance Score